Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV. Under the initial terms of the HBV license agreement, Arrowhead was eligible to receive a $50 million milestone payment linked to a Phase 2 study. Arrowhead and Janssen subsequently amended the HBV license agreement to accelerate the payment of $25 million of the $50 million Phase 2 milestone with the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining $25 million upon the initiation of a Phase 2 study by Janssen.
Is this the path Biotron may take. Especially considering the boards links to J&J. Not entering biotech showcase which they have for the past 10 years. Stephen coming on board as advisor I assume as this is his role with most other companies he is a part of. No update for nearly 6 months after reporting data from phase 2 trial. Is something actually in the works???
- Forums
- ASX - By Stock
- BIT
- The Glass is Half Full Thread.
The Glass is Half Full Thread., page-33
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 1050263 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 0.019 |
10 | 1774771 | 0.018 |
8 | 927388 | 0.017 |
12 | 3258350 | 0.016 |
10 | 1205000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 1050263 | 5 |
0.021 | 555000 | 2 |
0.022 | 997769 | 4 |
0.023 | 1449422 | 4 |
0.024 | 153949 | 2 |
Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |